Table 1.
Characteristics of participants in the DigiHero COVID-19 module
| All participants | Participants with confirmed prior COVID-19 | Participants without prior COVID-19 | |
|---|---|---|---|
| No. of participants | 318 | 258 | 36 |
| Sex | |||
| Female | 192 (60.4%) | 161 (62.4%) | 22 (61.1%) |
| Male | 126 (39.6%) | 97 (37.6%) | 14 (38.9%) |
| Age (years) | |||
| Median age | 51.3 | 51.2 | 50 |
| Range | 15–83 | 15–83 | 17–81 |
| Timing of COVID-19 infections | |||
| Wave 1 (March 2020–June 2020) | 7 (2.7%) | ||
| Wave 2 (July 2020–Feb 2021) | 198 (76.7%) | ||
| Wave 3 (Feb 2021–June 2021) | 45 (17.4%) | ||
| Wave 4 (from July 2021) | 8 (3.1%) | ||
| Self-rated acute infection severity | |||
| Asymptomatic | 15 (5.8%) | ||
| Mild to moderate | 221 (85.7%) | ||
| Severe | 22 (8.5%) | ||
| Hospitalization | 8 (3.1%) | ||
| Intensive care unit | 4 (1.5%) | ||
| Duration of symptoms | |||
| Not evaluated | 12 (4.7%) | ||
| 0–4 weeks | 71 (27.5%) | ||
| 4–12 weeks | 30 (11.6%) | ||
| >12 weeks | 145 (56.2%) | ||
| No. of SARS-COV-2 vaccinations | |||
| 0 | 62 (24%) | 6 (16.7%) | |
| 1 | 137 (53.1%) | 0 | |
| 2 | 59 (22.9%) | 30 (83.3%) | |
| Type of SARS-CoV-2 vaccine | 196 | ||
| Not evaluated | 25 (12.8%) | 1 (3.3%) | |
| mRNA vaccinea | 128 (65.3%) | ||
| mRNA vaccine + mRNA vaccine | 29 (14.8%) | 24 (80%) | |
| vector vaccinea | 7 (3.6%) | ||
| vector vaccine + vector vaccine | 3 (1.5%) | 1 (3.3%) | |
| vector vaccine + mRNA vaccine | 4 (2%) | 4 (13.3%) | |
Related to Figure 1, discovery cohort.
a
mRNA vaccines: Comirnaty (BioNTech/Pfizer) or Spikevax (Moderna Biotech), vector vaccines: Vaxzevria (AstraZeneca) or Ad26.COV2-S (Johnson & Johnson).